AbbVie, Allergan score FTC approval for $63B megamerger by Kyle Blankenship Tuesday, May 5, 2020 AbbVie and Allergan scored a long-awaited FTC approval for their $63 billion merger, which required offloading three Allergan drug candidates.
19. Allergan by Kyle Blankenship Irish drugmaker Allergan scored a major coup in 2019, courtesy of a $63 billion buyout offer from AbbVie. In return, Allergan will be bringing over longtime blockbuster Botox.
AbbVie touts Humira strategy abroad as a positive sign for U.S. by Kyle Blankenship Friday, February 7, 2020 AbbVie's Humira has faced a storm of copycats abroad, but executives are touting their strategy as a winner—and a positive sign for the future.
AbbVie-Allergan could look to asset sales to offset Humira loss by Kyle Blankenship Tuesday, January 7, 2020 Allergan's best-selling Botox and other promising meds may not be enough to fill the Humira gap. What could help? Hiving off assets, one analyst says.
Could AbbVie-Allergan lean on Vraylar scripts post-Humira? by Kyle Blankenship Thursday, December 19, 2019 AbbVie hopes its Allergan takeover will help it weather the storm of an aging Humira. Could the next-gen antipsychotic Vraylar be a solution?
Could AbbVie be a steal for investors as new meds take off? by Kyle Blankenship Friday, November 22, 2019 With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.
Allergan rolls new Vraylar ads focused on bipolar depression by Beth Snyder Bulik Monday, September 9, 2019 Allergan depicts the ups and downs of bipolar disorder with an elevator metaphor in its newest Vraylar ad campaign.
Allergan puts Vraylar on blockbuster track with new nod by Carly Helfand Tuesday, May 28, 2019 Allergan, badly in need of good news, finally has some to share with investors who've been clamoring for change.
Pharma TV ad spend beats last year, led by AbbVie and Pfizer by Beth Snyder Bulik Monday, October 15, 2018 With three quarters of pharma TV ad spending down and one to go, national media buys are tracking ahead of 2017, with brands doling out $2.81 billion.
Allergan focuses on biopolar mania in first DTC push for Vraylar by Beth Snyder Bulik Monday, April 9, 2018 Allergan’s new campaign for Vraylar is the antipsychotic's first—and the first DTC push to center on the manic side of bipolar disorder.
